RU2015111491A - Комбинация макроциклического ингибитора протеазы hcv, ненуклеозидного ингибитора hcv и ритонавира - Google Patents
Комбинация макроциклического ингибитора протеазы hcv, ненуклеозидного ингибитора hcv и ритонавира Download PDFInfo
- Publication number
- RU2015111491A RU2015111491A RU2015111491A RU2015111491A RU2015111491A RU 2015111491 A RU2015111491 A RU 2015111491A RU 2015111491 A RU2015111491 A RU 2015111491A RU 2015111491 A RU2015111491 A RU 2015111491A RU 2015111491 A RU2015111491 A RU 2015111491A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- amount
- formula
- approximately
- combination according
- Prior art date
Links
- 229940122604 HCV protease inhibitor Drugs 0.000 title claims abstract 3
- 239000003112 inhibitor Substances 0.000 title claims abstract 3
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 title description 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 title 1
- 239000002777 nucleoside Substances 0.000 title 1
- 229960000311 ritonavir Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 28
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims abstract 6
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 239000003443 antiviral agent Substances 0.000 claims abstract 4
- 229940124683 HCV polymerase inhibitor Drugs 0.000 claims abstract 2
- 239000002955 immunomodulating agent Substances 0.000 claims abstract 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims abstract 2
- 239000002552 dosage form Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12182551.7 | 2012-08-31 | ||
| EP12182551 | 2012-08-31 | ||
| EP12185890 | 2012-09-25 | ||
| EP12185890.6 | 2012-09-25 | ||
| PCT/IB2013/058138 WO2014033668A2 (en) | 2012-08-31 | 2013-08-30 | Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015111491A true RU2015111491A (ru) | 2016-10-20 |
Family
ID=49920362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015111491A RU2015111491A (ru) | 2012-08-31 | 2013-08-30 | Комбинация макроциклического ингибитора протеазы hcv, ненуклеозидного ингибитора hcv и ритонавира |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150209366A1 (enExample) |
| EP (1) | EP2890378A2 (enExample) |
| JP (1) | JP2015526504A (enExample) |
| KR (1) | KR20150046083A (enExample) |
| CN (1) | CN104780921A (enExample) |
| AU (1) | AU2013311025A1 (enExample) |
| BR (1) | BR112015003913A2 (enExample) |
| CA (1) | CA2881052A1 (enExample) |
| IL (1) | IL237049A0 (enExample) |
| MX (1) | MX2015002684A (enExample) |
| RU (1) | RU2015111491A (enExample) |
| WO (1) | WO2014033668A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI454476B (zh) | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物 |
| CN106727516A (zh) * | 2017-01-10 | 2017-05-31 | 山东省立医院 | 一种治疗丙型肝炎的药物组合物 |
| WO2020001814A1 (en) | 2018-06-27 | 2020-01-02 | Robert Bosch Gmbh | Method for operating a hybrid powertrain with an electric machine, an internal combustion engine and a variable transmission |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| PE20070211A1 (es) * | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| TWI454476B (zh) | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物 |
| SMT201700121T1 (it) * | 2009-02-27 | 2017-03-08 | Janssen Pharmaceuticals Inc | Sale amorfo di un inibitore macrociclico di hcv |
| MX2012011963A (es) * | 2010-04-13 | 2012-12-17 | Janssen Pharmaceuticals Inc | Combinacion de un inhibidor macrociclico del virus de la hepatitis c, un no-nucleosido y un nucleosido. |
-
2013
- 2013-08-30 JP JP2015529186A patent/JP2015526504A/ja active Pending
- 2013-08-30 BR BR112015003913A patent/BR112015003913A2/pt not_active IP Right Cessation
- 2013-08-30 WO PCT/IB2013/058138 patent/WO2014033668A2/en not_active Ceased
- 2013-08-30 CN CN201380045145.7A patent/CN104780921A/zh active Pending
- 2013-08-30 KR KR1020157005596A patent/KR20150046083A/ko not_active Withdrawn
- 2013-08-30 EP EP13818373.6A patent/EP2890378A2/en not_active Withdrawn
- 2013-08-30 CA CA2881052A patent/CA2881052A1/en not_active Abandoned
- 2013-08-30 MX MX2015002684A patent/MX2015002684A/es unknown
- 2013-08-30 US US14/422,005 patent/US20150209366A1/en not_active Abandoned
- 2013-08-30 AU AU2013311025A patent/AU2013311025A1/en not_active Abandoned
- 2013-08-30 RU RU2015111491A patent/RU2015111491A/ru not_active Application Discontinuation
-
2015
- 2015-02-02 IL IL237049A patent/IL237049A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014033668A2 (en) | 2014-03-06 |
| WO2014033668A3 (en) | 2014-05-01 |
| CA2881052A1 (en) | 2014-03-06 |
| JP2015526504A (ja) | 2015-09-10 |
| BR112015003913A2 (pt) | 2017-07-04 |
| US20150209366A1 (en) | 2015-07-30 |
| AU2013311025A1 (en) | 2015-02-26 |
| KR20150046083A (ko) | 2015-04-29 |
| MX2015002684A (es) | 2015-05-12 |
| IL237049A0 (en) | 2015-03-31 |
| EP2890378A2 (en) | 2015-07-08 |
| CN104780921A (zh) | 2015-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014122154A (ru) | Композиции, пригодные для лечения вирусных заболеваний | |
| RU2013119607A (ru) | Полициклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний | |
| EA201171376A1 (ru) | Производные тиено[2,3-b]пиридина в качестве ингибиторов репликации вируса | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2011528713A5 (enExample) | ||
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| HRP20120866T1 (hr) | Makrocikliäśni spojevi hinoksalina kao inhibitori hcv ns3 proteaze | |
| RU2014141362A (ru) | Комбинированная терапия пролиферативных нарушений | |
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| HRP20240082T1 (hr) | Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti | |
| EA200702445A1 (ru) | Соединения тиазола и способы их применения | |
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| RU2016141570A (ru) | Комбинации ингибитора fgfr и ингибитора igf1r | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| NO20076219L (no) | Farmasoytisk formulering med apomorfin for bukkal administrering | |
| WO2011118976A3 (en) | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| JP2015522033A5 (enExample) | ||
| RU2014139825A (ru) | Производные ингенола для реактивации латентного вируса вич | |
| RU2018123718A (ru) | Режимы дозирования мелфлуфена для раковых заболеваний | |
| RU2018110580A (ru) | Проникающее в мозг производное оксима хромона для терапии леводопа-индуцированной дискинезии | |
| RU2010138650A (ru) | Комбинация, включающая паклитаксел, для лечения рака яичников | |
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| RU2006131553A (ru) | Комбинация(а) ингибитора топоизомеразы днк и (б) ингибитора iap | |
| RU2013148627A (ru) | Производные тиено [2, 3-d] пиримидина и их применение для лечения аритмии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20171123 |